Hamit Bal
YOU?
Author Swipe
View article: Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes
Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes Open
Objective: The role of adjuvant chemoradiotherapy (CRT) following curative gastrectomy remains controversial, especially in the context of D2 dissection. This research evaluated survival indicators through an analysis of previous observati…
View article: Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study
Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study Open
In this largest-to-date real-world cohort of metastatic uterine leiomyosarcoma, doxorubicin-ifosfamide and gemcitabine-docetaxel demonstrated comparable survival outcomes. Gemcitabine-docetaxel, however, was associated with a more favorabl…
View article: Kanserde Takip
Kanserde Takip Open
-
View article: Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer
Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer Open
Background Tumor-infiltrating lymphocytes (TILs) have emerged as predictive biomarkers in HER2-positive breast cancer, correlating with treatment response and survival outcomes. This study evaluates the impact of TIL levels and Ki67 suppre…
View article: Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma
Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma Open
Introduction: Kidney cancer is an immunogenic tumor and inflammation plays a role in tumor formation and progression. The aim of this study was to investigate the effect of biochemical markers in predicting treatment response in patients w…
View article: Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer Open
Background and Objectives: Patients with human epidermal growth factor receptor 2 (HER2) -positive, hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) usually undergo trastuzumab emtansine (T-DM1) therapy in subsequent …
View article: Which Labarotory Index is Better for Predicting Survival and Pathological Response in Patients with Breast Cancer Receiving NACT?
Which Labarotory Index is Better for Predicting Survival and Pathological Response in Patients with Breast Cancer Receiving NACT? Open
Objective: Neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced, high-risk breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood-derived indices reflecting systemic inflammation a…